News | Computed Tomography (CT) | April 09, 2021

American Journal of Roentgenology: IV contrast-enhanced 2-millisievert CT comparable to conventional-dose CT for diagnosis of right colonic diverticulitis

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)


April 9, 2021 — According to an open-access article in ARRS' American Journal of Roentgenology (AJR), IV contrast-enhanced 2-millisievert CT (2-mSv CT) is comparable to conventional-dose CT (CDCT) for the diagnosis of right colonic diverticulitis.

"By mitigating concern of missed diagnosis of right colonic diverticulitis, our results further support the use of low-dose CT for suspected appendicitis," wrote first author Hae Young Kim from the department of radiology at Korea's Seoul National University Bundang Hospital. "To our knowledge," Kim et al. maintained, "this is the first study to formally measure the diagnostic performance of CT for right colonic diverticulitis."

Kim and colleagues' large pragmatic randomized controlled trial data included 3,074 patients (1,672 women, 1,402 men) aged 15-44 years old (median, 28 years) from 20 hospitals, randomized into 2-mSv (n = 1,535) or CDCT (median, 7-mSv; n = 1,539) groups from December 2013 to August 2016. A total of 161 radiologists prospectively issued CT reports, suggesting alternative diagnoses in 976 (2-mSV CT) and 924 (CDCT) patients.

In the intention-to-treat analysis, the between-group differences were minute with narrow 95% confidence intervals for most endpoints related to right colonic diverticulitis: test-positives (0.2%; p = .93), test-negatives (0.5%; p = .67), sensitivity (0.0%; p > .99), and specificity (0.2%; p = .66). The characteristics and disposition of test-positive patients were similar between the two groups.

"We believe our results reflect what can be expected in real-word conditions, owing to the pragmatic nature of the trial design, whereby we tried to deliver the intervention with the actual resources used in daily clinical practice," the authors of this AJR article added.

For more information: www.arrs.org

Related Content

News | Teleradiology

August 17, 2022 — In a study published today in the Journal of General Internal Medicine, researchers at the Icahn ...

Time August 17, 2022
arrow
News | X-Ray

August 17, 2022 — The Institute of Human Virology in Nigeria (IHVN) has announced their partnership with Fujifilm, the ...

Time August 17, 2022
arrow
News | Prostate Cancer

August 16, 2022 — A new study published by University of Kentucky Markey Cancer Center researchers suggests that the ...

Time August 16, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time August 12, 2022
arrow
News | Radiology Education

August 11, 2022 — After a three-year break, this spring featured the return of the anticipated Canon Roadshow Events ...

Time August 11, 2022
arrow
News | Computed Tomography (CT)

August 11, 2022 — For the first time, researchers successfully captured CT images of an entire woolly mammoth tusk ...

Time August 11, 2022
arrow
News | Radiology Imaging

August 11, 2022 — Bracco Imaging S.p.A. has announced the renewal of the “Bracco Fellowships” initiative, in partnership ...

Time August 11, 2022
arrow
News | Ultrasound Imaging

August 10, 2022 — Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ...

Time August 10, 2022
arrow
News | Point-of-Care Ultrasound (POCUS)

August 10, 2022 — Mindray North America, a global leader and developer of healthcare technologies and solutions for ...

Time August 10, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
Subscribe Now